Reporter Zhang Lei

　　What is the situation of the new coronavirus variants emerging in India? When vaccination is found to contain flocs in the bottle, does it affect the vaccination effect? ​​Can two doses of inactivated vaccine be vaccinated with products from different manufacturers? The Joint Prevention and Control Mechanism of the State Council will be in Beijing on May 20 At a press conference, relevant experts from the China Centers for Disease Control and Prevention and the vaccine research and development team answered questions from the media on the above-mentioned hot issues.

　　my country's vaccine can deal with mutant strains

　　Wu Zunyou, chief epidemiology expert of the Chinese Center for Disease Control and Prevention, said that the World Health Organization has a global new coronavirus mutation monitoring network, and all countries must report to this network the newly emerging mutated strains in their country. It can be seen on this monitoring network that more than 3,000 mutated strains have been reported in India. Since the monitored cases account for only a small part of the total cases, the actual number of mutant strains far exceeds this number.

　　"It's not that the more mutated strains, the more terrible it is. The key depends on the nature of the virus mutation." Wu Zunyou said, the WHO divides the virus mutation into three major categories: The first category is particularly "mutated strains that require vigilance", such as the United Kingdom , Brazil mutant strains; the second category is "variant strains worthy of attention", India's mutant strains belong to this category; the third category is "mutant strains that do not need to be concerned", minor mutations do not require attention.

　　So, can the domestically produced new crown vaccine cope with the variant strains that emerged in India? Shao Yiming, a researcher at the Chinese Center for Disease Control and Prevention, said that research is being carried out on the newly emerging variant strains of the new crown in India. "At present, there are two things that need to be informed to the public." Shao Yiming said. First, relevant companies and research institutions in my country are closely tracking the virus mutation and carrying out targeted research. Preliminary results show that my country's vaccine can still deal with the new coronavirus variants emerging in India. Second, if there is a mutant virus strain that cannot be dealt with by the vaccine, there is no need to change the production process of inactivated vaccines in my country. It is only necessary to change the original vaccine strain to a new mutant strain at the feed end of the production, and then a new mutant strain-specific strain can be produced. vaccine. Therefore, the public can rest assured that my country's vaccine is fully capable of responding to the challenge of the new coronavirus variant.

　　Only after passing the inspection batch by batch can it be released on the market

　　Recently, the public reported that a bottle of vaccine was found to be used by two people during vaccination, and they were worried that insufficient dosage would affect the effect of vaccination. In this regard, Shao Yiming explained that the two-dose domestic new crown vaccine and the one-dose new crown vaccine are the same in terms of raw and auxiliary materials, production formula, packaging materials, and process parameters. The difference is whether the filling amount is one dose or two doses. . "In order to ensure that everyone injects enough, each bottle is sufficient, so the public does not need to worry about insufficient dosage. Internationally, vaccines from many countries, including vaccines exported from my country, are administered in multiple doses, such as 5 doses. , 10 doses are available. Its advantage is that it can transport more vaccines in the same time, saving packaging materials and transportation capacity for large-scale vaccination." Shao Yiming said.

　　Some members of the public expressed that they found floccules in the bottle when they were vaccinated with the new crown vaccine, worrying about the quality of the vaccine. In this regard, Shao Yiming explained that the new crown vaccine produced by various manufacturers in my country must undergo self-inspection by the manufacturer in accordance with national standards, and at the same time, it must be submitted to the drug inspection agency for batch-by-batch inspection before it can be released on the market. Each finished product of the new crown vaccine that has been subpackaged goes through a strict inspection process, and the unqualified products are directly rejected. After the inspection, the finished product must be sampled for appearance inspection, which must meet the requirements of "should be a milky white suspension." , Can be stratified due to precipitation, easy to shake "requirements, so the new crown vaccines that everyone has observed are often not clear and transparent. Since the new crown vaccine contains an aluminum adjuvant, standing before use may cause precipitation, but it should be able to be shaken.

　　In addition, after vaccination, some members of the public found that the two doses were produced by different manufacturers. For example, the first dose was Beijing Biotech and the second dose was Beijing Kexing. They were worried that "mixing" would affect the effect of vaccination. In this regard, Wang Huaqing, chief expert of the China Centers for Disease Control and Prevention's immunization program, said that the current domestically-made new coronavirus vaccines on the market have three technical routes: inactivated vaccines, adenovirus vector vaccines and protein subunit vaccines. As long as they are vaccines with the same technical route, Products from different manufacturers will not affect the inoculation effect. "It is clear in the Technical Guidelines for Vaccination against New Coronavirus that at this stage it is recommended to use the same vaccine product to complete vaccination. In case of special circumstances such as the inability to continue supply of vaccines and the recipients being vaccinated in different places, the same vaccine product cannot be used to complete vaccination. The same type of vaccine products from other manufacturers can be used to complete the vaccination." Wang Huaqing said that if the vaccine requires two or more doses to complete the entire immunization process, if the prescribed interval is exceeded, generally follow-up vaccination does not need to be restarted. For example, if the inactivated vaccine has not been given a second dose after more than 8 weeks, there is no need to re-vaccinate, and the second dose can be supplemented as soon as possible.